Ganoderic acid D

Research use only, not for human use.

Ganoderic acid D is one of the major components in Ganoderma triterpenes.

Ganoderic acid D is one of the major components in Ganoderma triterpenes. 2. Ganoderic acid D treatment for 48h inhibits the proliferation of HeLa human cervical carcinoma cells with an IC(5) value of 17.3 +/- .3 microM.

Ganoderic acid D can inhibit the growth of numerous cancer cell lines and it inhibits HeLa human cervical carcinoma cells with an IC50 of 17.3 mM.Ganoderic acid D (1-50 μM; 24-72 hours) reduces the cell survival rate in a dose- and time-dependent manner. Ganoderic acid D (10, 50 μM; 24, 48 hours) induces G2/M phase arrest.Ganoderic acid D (10, 50 μM; 24, 48 hours) induces a morphological change typical of apoptosis in HeLa cells. Ganoderic acid D (10 μM; 48 hours) up-regulates 14-3-3E and PRDX3. Cell Viability Assay Cell Line:HeLa human cervical carcinoma cell line (CCL-2) Concentration:1, 5, 10, 20, 50 μM Incubation Time:24, 48, 72 hours Result:Reduced the cell survival rate in a dose- and time-dependent manner and had an IC50 value of 17.3 μM for 48 hours treatment.Cell Cycle Analysis Cell Line:HeLa human cervical carcinoma cell line (CCL-2) Concentration:10, 50 μM Incubation Time:24, 48 hours Result:Induced G2/M phase arrest. Displayed a cell cycle profile with an elevated G2/M cell population after 24-h treatment with 10 μM. Apoptosis Analysis Cell Line:HeLa human cervical carcinoma cell line (CCL-2) Concentration:10, 50 μM Incubation Time:48 hours Result:Induced a morphological change typical of apoptosis in HeLa cells. Western Blot Analysis Cell Line:HeLa human cervical carcinoma cell line (CCL-2) Concentration:10 μM Incubation Time:48 hours Result:Up-regulated 14-3-3E and PRDX3.

——

——

Others

Antioxidant

Others

——

——

108340-60-9

514.65

C30H42O7

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (194.31 mM)

CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(CC(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C

——

(-20℃)

With Ice Pack

≥ 2 years